share_log

JMP Securities Reiterates Market Outperform on Jasper Therapeutics, Maintains $70 Price Target

Benzinga ·  Oct 16 00:16  · Ratings

JMP Securities analyst Silvan Tuerkcan reiterates Jasper Therapeutics (NASDAQ:JSPR) with a Market Outperform and maintains $70 price target.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment